Condition: Melanoma Stage IV · Solid Tumor · Sponsor: Georgiamune Inc
GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).
This description comes directly from the study's public registry record.
Jayadev Sureddi, CBCC CRO · (661) 616-6453 · jayadev.sureddi@cbcc.global
Always discuss trial participation with your own doctor first.
| HonorHealth Research Institute | Scottsdale, Arizona, United States | Recruiting |
| Comprehensive Blood and Cancer Center | Bakersfield, California, United States | Recruiting |
| Providence Medical Foundation | Fullerton, California, United States | Recruiting |
| The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate | Los Angeles, California, United States | Recruiting |
| UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco, California, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana | Billings, Montana, United States | Recruiting |
| Weill Cornell Medicine - New York Presbyterian Hospital | New York, New York, United States | Recruiting |
| University of Cincinnati Cancer Center | Cincinnati, Ohio, United States | Recruiting |
| Tennessee Oncology, PLLC | Nashville, Tennessee, United States | Recruiting |
| Virginia Commonwealth University | Richmond, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06425926